Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mirvetuximab soravtansine + pembrolizumab
- Development stage
- Unknown
- Lead developer
- ImmunoGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Mirvetuximab soravtansine + pembrolizumab** is a combination of an antibody-drug conjugate and a checkpoint inhibitor used in clinical trials primarily for platinum-resistant ovarian cancer. Mirvetuximab soravtansine targets folate receptor alpha (FRα) on tumor cells and delivers the cytotoxic agent DM4, a maytansinoid that disrupts microtubules, leading to cell death. Pembrolizumab is a humanized monoclonal antibody that blocks PD-1, enhancing T-cell immune responses against tumor cells. The combination aims to increase immunogenic cell death and augment antitumor activity, as supported by clinical trial data showing objective responses and a manageable safety profile in heavily pretreated patients with platinum-resistant ovarian cancer[1][4].
- Brand names
- ElahereKeytruda
- Other names
- mirvetuximab soravtansine plus pembrolizumab
02
Targets
FOLR1 (FRα)TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on mirvetuximab soravtansine + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mirvetuximab soravtansine + pembrolizumab.